Persistence of mucosal and systemic immune responses following sublingual immunization

Vaccine

Volumn 28, Issue 25, 2010, Pages 4175-4180

  Negri, Donatella R M ^a   Riccomi, Antonella ^a   Pinto, Dora ^a   Vendetti, Silvia ^a   Rossi, Alessandra ^a   Cicconi, Rosella ^a   Ruggiero, Paolo ^b   Del Giudice, Giuseppe ^b   Magistris, Maria Teresa De ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Antibody secreting cells; Bacterial toxin; Mucosal adjuvant; Sublingual immunization

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN LACKING ADP RIBOSYLTRANSFERASE ACTIVITY; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL TOXINS; BACTERIAL VACCINES; BONE MARROW; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNITY, MUCOSAL; LYMPH NODES; MICE; MICE, INBRED BALB C; SPLEEN; TETANUS TOXOID;

EID: 77952671933     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.013     Document Type: Article

References (24)

1. De Magistris M.T. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 58 1 (2006) 52-67
2. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 4 Suppl. (2005) S45-53
3. Mitragotri S. Immunization without needles. Nat Rev Immunol 5 12 (2005) 905-916
4. van Ginkel F.W., Jackson R.J., Yuki Y., and McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165 9 (2000) 4778-4782
5. Armstrong M.E., Lavelle E.C., Loscher C.E., Lynch M.A., and Mills K.H. Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. J Infect Dis 192 9 (2005) 1628-1633
6. Lemiale F., Kong W.P., Akyurek L.M., Ling X., Huang Y., Chakrabarti B.K., et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 77 18 (2003) 10078-10087
7. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350 (2004) 896-903
8. Passalacqua G., and Canonica G.W. Sublingual immunotherapy: update 2006. Curr Opin Allergy Clin Immunol 6 6 (2006) 449-454
9. Durham S.R. Sublingual immunotherapy: what have we learnt from the 'big trials'?. Curr Opin Allergy Clin Immunol 8 6 (2008) 577-584
10. BenMohamed L., Belkaid Y., Loing E., Brahimi K., Gras-Masse H., and Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur J Immunol 32 8 (2002) 2274-2281
11. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25 51 (2007) 8598-8610
12. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 105 5 (2008) 1644-1649
13. Huang C.F., Wu T.C., Chu Y.H., Hwang K.S., Wang C.C., and Peng H.J. Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice. Scand J Immunol 68 5 (2008) 502-510
14. Song J.H., Kim J.I., Kwon H.J., Shim D.H., Parajuli N., Cuburu N., et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J Immunol 182 11 (2009) 6851-6860
15. Rappuoli R., Pizza M., Douce G., and Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 20 11 (1999) 493-500
16. Pizza M., Giuliani M.M., Fontana M.R., Monaci E., Douce G., Dougan G., et al. Mucosal vaccines: nontoxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19 17-19 (2001) 2534-2541
17. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4 9 (2009) e6999
18. Jackson R.J., Fujihashi K., Xu-Amano J., Kiyono H., Elson C.O., and McGhee J.R. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 61 10 (1993) 4272-4279
19. Bagley K.C., Abdelwahab S.F., Tuskan R.G., Fouts T.R., and Lewis G.K. Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway. Infect Immun 70 10 (2002) 5533-5539
20. Gagliardi M.C., Sallusto F., Marinaro M., Langenkamp A., Lanzavecchia A., and De Magistris M.T. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol 30 8 (2000) 2394-2403
21. Gagliardi M.C., and De Magistris M.T. Maturation of human dendritic cells induced by the adjuvant cholera toxin: role of cAMP on chemokine receptor expression. Vaccine 21 9-10 (2003) 856-861
22. Negri D.R., Pinto D., Vendetti S., Patrizio M., Sanchez M., Riccomi A., et al. Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes. Infect Immun 77 5 (2009) 1924-1935
23. Peppoloni S., Ruggiero P., Contorni M., Morandi M., Pizza M., Rappuoli R., et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2 2 (2003) 285-289
24. Tritto E., Muzzi A., Pesce I., Monaci E., Nuti S., Galli G., et al. The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. J Immunol 179 8 (2007) 5346-5357